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Cholecystokinin (CCK) and the structurally related peptide, gastrin, have
numerous effects on tissues in the central nervous system and gastrointestinal
tract. Recent studies show these effects are mediated by a CCKA and CCKB
receptor. Knowledge of the physiological role and role ofCCKR receptors in
pathologic processes has been particularly limited by the availability of selec-
tive, potent receptor antagonists. Recently, new members offive different class-
es of non-peptide CCKB receptor antagonists are reported and are reviewed
briefly. These include compounds isolated from Streptomyces (tetronothiodin,
virginiamycin analogues), ureido-acetamide analogues (RP 69758, RP 72540,
RP 73870), newer benzodiazepine analogues (L-368,935, L-740,093, YM022),
pyrazolidimine analogues (LY 262,691) and glutamic acid analogues (CR2194).
Many ofthese compounds have greater than 1000-fold selectivity for the CCKB
overtheCCKA receptor and some have greater than 10,000-fold selectivity. The
pharmacology and effects ofCCKB receptor antagonists on gastric acid secre-
tion is briefly reviewed. Furthermore, the possible clinical usefulness ofCCKB
receptor antagonists in treating disorders ofgastric acid secretion, in inhibiting
thetrophic effects ofgastrin and in other clinical conditions is briefly discussed.
INTRODUCTION
In this article, recent advances in the identification of selective cholecystokinin B
(CCKB)b (gastrin) receptor antagonists will be briefly reviewed and their possible thera-
peutic role in the treatment of gastric secretory disorders briefly discussed. To address
these questions, it is important first to have a general understanding of the role of CCK
receptors in different processes as well as to understand the recent advances in classifying
receptors that mediate the action ofCCK and gastrin-related peptides. These areas will be
briefly reviewed first.
I. CLASSIFICATION OF CCK RECEPTORS AND THEIR
ROLES IN DIFFERENT PHYSIOLOGICAL PROCESSES
Cholecystokinin (CCK) structurally closely resembles gastrin at its carboxyl termi-
nal, which is the biological active portion of the peptide [1-7]. Both peptides end in the
pentapeptide gly-trp-met-asp-phe-NH2 [2, 8]. However, they differ in the presence or
absence of a sulfated tyrosine in position 7 from the carboxy-terminal phenyalanine
amide. The presence ofthis group is the primary determinant ofhigh affinity to cause the
classical actions of CCK of stimulating pancreatic secretion and gallbladder contraction
[2-5, 7, 8]. Recent studies demonstrate CCK immunoreactivity is widely distributed in the
central nervous system (CNS) and gastrointestinal tract(in duodenal I cells and in nerves),
whereas gastrin immunoreactivity is more localized, occurring predominantly in gastric
antral and duodenal G cells, with low levels in various neuroendocrine tissues (pituitary,
aTo whom all correspondence should be addressed: Dr. Robert T. Jensen, National Institutes of
Health, Building 10, Room 9C-103; 10 CENTER DR MSC 1804, Bethesda, MD 20892-1804. Tel:
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bAbbreviations: CCK, Cholecystokinin; CNS, central nervous system; GRP, gastrin-releasing pep-
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adrenal medulla, vagus), genital tract and respiratory tract [6, 9]. CCK has been shown to
have effects on many tissues including in the CNS (functioning as a neuromodulator, mod-
ulation ofdopaminergic activity and opioid analgesia) [4, 10]; to have growth effects (pan-
creas, various tumor issues) [4, 6, 11]; to stimulate pancreatic secretion of water, elec-
trolytes, enzymes and insulin [4, 12-14]; to have motility effects (contraction of the gall-
bladder, intestinal smooth muscle, delay gastric emptying and colon motility) [4, 14, 15];
to have gastric secretory effects (stimulate pepsinogen release, somatostatin release from
D-cells, inhibit acid secretion) [4, 16-19]; and to stimulate peripheral neural effects
(vagally mediated satiety) [10]. Gastrin also has been shown to cause many ofthe changes
mediated by CCK in various tissues [10]; to have stimulatory effect on gastric acid secre-
tion, [9]; to have trophic effects on the gastric mucosa, particularly on gastric enterochro-
maffin-like cells [9]; to have growth stimulatory effects on numerous tumors [6, 9, 11];
and to have CNS effects (anxiogenic action) [4, 20].
Numerous pharmacological, biological, and now structural studies provide evidence
that two classes ofCCKreceptors mediate the actions ofCCK and gastrin: aCCKA recep-
tor and a CCKB receptor [21-25]. The gene encoding the CCKA receptor has been cloned
Table 1. Comparison of CCKA and CCKB receptors.
CCKA receptors CCKB receptors
Structure 428AA (human) 447AA (human)
474AA (rat) 452AA (rat)
Signaling pathway PLC PLC
Natural agonists CCK-8>>G171=CCK-4 CCK, G1711>G171>>CCK-4
Selective agonists A-71378 A72962
SNF-8702
Cyclic compound II
Gastrin
Older selective L364, 718 (devazepide) CI-988 (PD134, 308)
antagonists Lorglumide (CR1409) L365, 260
Distribution CNS (limited), islets, CNS (general), GI
pan. acini, gallbladder Smooth muscle,
muscle, neurons (GI tract) Pan. acini
Gastric location Chiefcells, D cells Chiefcells (some species),
Parietal cells (dog), ECL cells (rat,
dog), D cells (dog), neurons in
circular muscle layer, myentric
plexus, gastric smooth muscle
Abbreviations: PLC-phospholipase C; CNS-central nervous system; G171 and G17II-refer to the
nonsulfated and sulfated analogues of gastrin-17. CCK-8 and CCK-4 are the COOH terminal
octapeptide and tetrapeptide ofcholecystokinin. A-71378-[des amino, Nle28' 31, N-methyl Asp32]
CCK-27-33(7); A72962-[des amino-Nle28 N-methyl-Leu31]CCK-27-33(28), SNF-8702-[N-
methyl-Nle2 31]CCK(26-33)(30); cyclic compound II-BOC-y-D-Glu26, Tyr(SO3H)-Ahx-DLys-
Trp-Ahx- Asp-Phe-NH2 (Ahx=2 aminohexanoic acid) (29); L364, 718 (MK-329, devazepide)
[3S(-)-N(L2, 3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1, 4-benzodiazepin-3-yl)- 1-H-idole-2-car-
boxide. Loxiglumide (CR1409)-D, L-4-(3, 4-dichlorobenzoyl amino)-5-(dipentyl amino)-5-oxo-
pentanoic acid. The structures of L-365, 260 and CI- 988 are shown in Figure 1. Data are from
References [12, 23, 25, 27, 32, 44].
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from numerous species and in the human DNA sequence predicts a protein that has 428
amino acids and is a member ofthe G protein-coupled superfamily ofreceptors with seven
spanning areas [21, 23] (Table 1). The CCKB receptor, originally characterized best phar-
macologically in the CNS, is now known to be the same as the gastrin receptor originally
characterized in parietal cells [21, 23, 24, 26, 27]. The CCKB receptor gene has also been
cloned from numerous species and the predicted human protein has 447 amino acids, 48
percent homology with the human CCKA receptor and is also a member ofthe G protein-
coupled heptahelical superfamily [21, 23, 24, 26, 27]. The CCKA receptor and CCKB
receptor differ from each other in their affinities for natural agonists (Table 1), distribu-
tion (Table 1), affinity for certain selective agonists (Table 1) [12, 2, 8-30] and antagonists
(Tables 1 and 2). Of the many actions of CCK and gastrin on different tissues, CCKA
Table 2.Affinities ofrecently described CCKB receptor antagonists for rat CCKA and CCKB
receptors.
Ki or IC 0(nM) Fold
Antagonist rCCKA-R rCCKZ-R CCKB-preferring Ref.
L-365, 260(l) 1, 170 11 106 [61,47]
CR-2194(2) 13, 500 1.00 23 [64]
LY-262, 691(3) 11, 500 31(m) 370 [65]
Tetronothiodin >10, 000 3.6 27, 000 [50]
L-156, 586(4) >40, 000 90 444 [50, 51]
CI-988 (PD-134, 308)(5) 6, 600 6.3 1, 048 [47, 36]
Benzodiazepines
YM022(6) 63 0.068 926 [47]
L-740, 093(7) 1, 600 0.1O(GP) 16, 000 [62]
Ureido-acetamides
RP69758(8) 4, 734 4.3 1, 182 [61]
RP72540(9) 2,756 1.2 2, 300 [61]
RP73870'00) 1, 634(GP) 0.48(GP) 3, 404 [62]
Acidic benzodiazepine
L-368, 935(l1) 1, 400 0.14(GP) 10, 000 [54]
All data are affinities from binding studies using primarily 1251-BH-CCK-8 and are for rat pancreas
(rCCKA-R), rat cortex or gastric glands (rCCKB_R) except those indicated by GP which are from
guinea pig and m which are from mouse.
1. L-365, 260-3R(+)-(N-2, 3-dihydro-1-methyl-2-oxo-5-phenyl-1 H-1, 4-benodiazepin-3-yl)-N'-(3-
methylphenyl)urea.
2. CR 2194-(R)-4-(3, 5-dichlorobenzamido)-5-(8-azaspiro-[4.5]decan-8-yl)-5-oxo-pentanoic acid.
[64].
3. LY-262, 691-1-(4-bromophenylaminocarbonyl)-4, 5-diphenyl-3-pyrazolidinone [65].
4. L-156, 586 15-dihydro-13, 14-anhydro-virginamycin M1 [51].
5.CI-988-4-[[2-[[3-(1H-indol-3-yl)-2-methyl- 1-oxo-2[[(tricyclo[3.3[[2 17]dec-2-yloxy)-
carbonyl]amino]-propyl]amino]-l-phenyethyl]amino]-4oxo-[R-(R*, R*)]-butanoate N-methyl-D-
glucamine [36]
6. YM022 {(R)-1-[2, 3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl-1H-1, 4-benzodiazepin-3-
yl]-3-(methylphenyl)urea} [47].
7. L-740, 093-[N-[[(3R)-5-(3-azabicyclo[3.2.2]nonan-3-yl)-2, 3-dihydro-1-methyl-2-oxo-1H-1, 4-
benzodiazepin-3-yl]-N'-(3-methylphenyl)urea] [57].
8. RP 69, 758-(3-{3-[N-(N-methyl N-phenyl-carbamoylmethyl)N-phenyl-carbamoylmethyl]urei-
do)phenylacetic acid [61].
9. RP 72540 [(RS)-{3-{3-[N-(3-methoxyl phenyl) N-(N-methyl N-phenyl-carbamoylmethyl)car-
bamoylmethyl]ureido}phenyl)propionic acid [61].
10. RP 73870 { {[N-(methoxy-3-phenyl)-N-(N-methyl-N-phenyl-carbamoylmethyl)-carbamoyl-
methyl]-3-ureido)-3- phenyl)-2-ethylsulfonate-(RS) [62].
11. L-368, 935 (N-(l, 3-dihydro-1-(2-methyl)propyl-2-oxo-5-phenyl-1 H-1, 4-benzodiazepin-3-yl)-
N-((3-(lH-tetrazol-5-yl)phenyl)urea) [54].
247Jensen: CCKB-R antagonists
receptors [4, 9, 23] are thought to mediate CCK-stimulated pancreatic enzyme, electrolyte
and insulin secretion; pancreatic growth, gastric effects (pepsin release, acid inhibition,
somatostatin release from D-cells); motility effects (decreased gastric and colonic motili-
ty); gallbladder effects (contraction of gallbladder and relaxation of the sphincter of
Oddi); and some CNS or neural effects (satiety, opioid and analgesic effects). CCKB
receptors are thought to mediate stimulation of gastric acid secretion, trophic effects on
ECL cells and gastric mucosa and some CNS effects (anxiety attacks). Which of these
actions are pharmacological and which are physiological are at present unclear in most
cases. Furthermore, because CCK can interact with high affinity with both CCKA and
CCKB receptors [4, 23, 25, 31], in many cases, whether CCKA or CCKB receptors medi-
ate many actions of CCK remains unclear. Only with the recent availability of selective
antagonists will this become clear.
II. RECENT ADVANCES IN THE DEVELOPMENT OF POTENT,
SPECIFIC CCKB RECEPTOR ANTAGONISTS
Until recently, CCK receptor antagonists with only limited selectivity for CCKB
receptors existed [32]. Whereas the benzodiazepine analogue, L-364, 718, and the prog-
lumide analogue, lorglumide (CR 1409), or the closely related compound, loxiglumide
(CR 1505), have proven to have sufficient selectivity for CCKA receptors both in vitro and
in vivo to define the role of CCKA receptors in various processes, this has not been the
case with the selective CCKB receptor antagonists benzodiazapine analogue, L-365, 260
or the dipeptoid compound, CI-988 (PD 134, 308) (Table 1). The use of L-365, 260 has
been limited by its relatively low selectivity and also its use has been limited in dogs by a
reversal of the affinities ofL-364, 718 and L-365, 260 for CCKB receptors, as well as the
low selectivity ofboth antagonists in this species [21, 26, 33]. A recent study demonstrates
that the difference in selectivity of L-365, 260 and L-364, 718 for human and rat CCKB
receptors compared to canine CCKB receptors is due primarily to the substitution of
leucine in the canine CCKB receptor for valine in the equivalent position (valine) in the
6th transmembrane region of the human CCKB receptor [26, 33]. Although CI-988 (PD-
134, 308) has more than 1000-fold selectivity for CCKB receptors over CCKA receptors
(Table 2), its general usefulness has been limited by recent reports that this compound has
agonist activity in some systems. PD-136, 450 (also called Cam-1189) is a dipeptoid ana-
logue closely related to PD-134, 308, and it has been shown recently to function as a par-
tial CCKB receptor agonist in the rat stomach for acid secretion [34], and as a full agonist
at CCKA receptor for stimulating pancreatic enzyme secretion in rats [34, 35].
Furthermore, PD-135, 158, which is also closely related to PD-134, 508 [36], also func-
tions as a CCKA receptor agonist in rat pancreatic acini [37]. Recent studies have demon-
strated marked species differences in agonist/antagonist activity ofvarious classes ofpep-
tide antagonists to other receptors. For example, various classes of peptide antagonists of
the gastrin peptide-releasing receptors such as bombesin pseudopeptides, des Metl4
bombesin amides and alkyl amides are excellent gastrin-releasing peptide (GRP) receptor
antagonists in mouse and guinea pig but function as GRP receptor agonists or partial ago-
nists in rats [38-40]. Similarly, chimeric galanin peptide receptor antagonists such as
galantide [41] and CCK peptide analogues such as CCK-(26-32)NH2, function as ago-
nists, partial agonists and antagonists in different species [42]. These data suggest that
mixed agonist/antagonist activity in different species or cell systems may be a general
property ofmany peptide analogues that function as antagonists in some assays.
Recently, a number of different classes of highly selective non-peptide CCKB recep-
tor antagonists have been described (Table 2, Figure 1). Some of these compounds have
>2000-fold selectivity for CCKB receptors (Table 2, Figure 1) compared to L-365, 260
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Tetronothiodin (,A=27,000)
rOCONH ,CK CONH NHCOLCO2H
PD 134308 (CI-988) (B-14)
RP 72540 ( =2300)
Figure 1. Structure of newer CCKB receptor antagonists. The A/B ratio refers to the relative
affinity of the indicated compound for rat CCKA receptors compared to its affinity for rat CCKB
receptors. Numbers greater than 1 indicate the number of times the compound is selectivity for
CCKB over CCKA receptors. Ratios are calculated from the affinities listed in Table 2. The struc-
tures of four different classes of CCKB receptor antagonists are shown. Shown are the benzodi-
azepine analogues related to the prototype compound L-365, 260 which include L-740, 073,
YM022, L-368, 935, the natural occurring compound, tetronothiodin isolated from Streptomyces,
the dipeptoid analogue CI- 988 and the ureido-acetamide analogue RP-72540.
which has a selectivity of 80-280-fold for the CCKB over the CCKA receptor in different
species (Table 1) and a five- to 180-fold selectivity in human transfected CCK receptors
[21, 23, 43-47]. In general, the new CCKB receptor antagonists fall into five different
chemical groups: tetronothiodin and other compounds isolated from Streptomyces, urei-
do-acetamide analogues, benzodiazepine analogues, glutaramic acid analogues orproglu-
mide analogues, and pyrazolidinone analogues.
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Tetronothiodin has a 19-membered ring with an alpha-acyltetronic acid and atetrahy-
drothiophene moiety (Figure 1) and was isolated from the culture broth ofStreptomyces
sp. NR0489 [48, 49]. Tetronothiodin is completely different structurally from any of the
otherCCKB receptorantagonists (Figure 1) including the virginiamycin analogues L-156,
586, L-156, 587 and L-156, 588, which were also selective CCKB antagonists and were
isolated from Streptomyces olivaceus [49-51] and from asperlicin, a CCKA receptor
antagonist isolated fromAspergillus alliaceus [52]. A recent study [50] reports that while
tetronothiodin has high affinity (affinity constant [Kj] = 3.6 nM) for CCKB receptors in
the rat and a 27, 000 selectivity for rat CCKB over rat CCKA receptors (Table 2), it has a
80-fold (KI = 280 nM) and 60-fold (Ki = 210 nM) lower affinity for mouse and human
CCKB receptors (cerebral cortex) than for rat CCKB receptors. Tetronothiodin functions
as a selective CCKB receptor competitive antagonist in the rat [50, 53], however its lower
affinity may limit its usefulness in humans and mice.
The newer benzodiazepine CCKB receptor antagonists include various 1, 4-benzodi-
azepine derivatives including ones containing an acidic group on the phenylurea portion
of L-365, 260 (Figure 1), such as the tetrazole derivative L-368, 935 [54, 55] (Figure 1).
L-368, 935 has much greater water solubility than L-365, 260, very high selectivity for
CCKB receptors (Table 2) and also has high affinity for human CCKB receptors (K, = 27
nM) [54]. L-368, 935 is active in vivo blocking pentagastrin-stimulated acid secretion in
rats with an ED50 of 0.14 mg/Kg [intraperitoneal (i.p.), compared to an ED50 of 0.83
mg/Kg for L- 365, 260 (i.p.) [54, 55]. Using an ex vivo binding model in the mouse brain
and other studies, it was demonstrated this compound does penetrate the CNS, although
to a lesser extent than L-365, 260 [54, 55]. To improve the brain penetrance, a series of
amidine 5-amino-1, 4-benzodiazepine analogues which had an amine-based cationic
group within the benzodiazepine moiety were synthesized [56, 57] and the azabicyclo-
nanane derivative L- 740, 093 was identified and fully characterized [56, 57] (Figure 1).
L-740, 093 has a very high affinity for guinea pig CCKB receptors (concentration causing
half-maximal inhibition, [IC50]- 0.10 nM) and a 16, 000-fold selectivity for CCKB over
CCKA receptors (Table 2). L-740, 093 blocks pentagastrin-induced gastric acid secretion
with anED50 of0.01 mg/Kg which is 100-times more potent than L-365, 260. L-740, 093
has a much greater watersolubility than L-365, 260 and also has greaterthan 60-increased
activity in the ex vivo brain binding assay, suggesting much greater CNS penetration [56-
58]. The 5-phenyl-1, 4-benzodiazepine analogue, YM022, is also a potent CCKB receptor
antagonist in the rat (KY = 0.068 nM) (Table 2) and has greater than 100-fold selectivity
for CCKB over CCKA receptors [47, 59]. Administration ofYM022 inhibited pentagas-
trin-induced gastric acid secretion with an ED50 of0.0078 gm/Kg and was 540-fold and
129-fold more potent than L-365, 260 (concentration causing half-maximal stimulation
[EC50]-4.23 ,umol/Kg) and CI-988 (EC50 = 1.01 jimol/Kg), respectively [47]. In contrast
to L-365, 260, neither YM022 nor CI-988 inhibited histamine or bethachol-stimulated
acid secretion, whereas L-365, 260 inhibited both [47]. YM022 orally dose-dependently
inhibited acid secretion in pylorus-ligated rats with an ED50 of 0.83 imolKg compared
to 1.6gmol/Kg for famotidine and 10.9 imol/Kg for omeprazole [59]. In rats, YM022 is
as potent as famotidine at preventing in rats indomethacin-induced gastric lesions, gastric
damage caused by water-immersion and restraint, gastric erosions caused by acidified
ethanol and mepirizole-induced duodenal ulcers [59]. Recently, a series of imidazo 1, 4-
benzodiazepine analogues have been reported [60]. Compound 12 in this series (N-[(2S,
4R)-methyl- 6-phenyl-2, 4-dihydro-lH-imidazo[1, 2-a][1, 4]benzodiazepin-4-yl]-N'-[3-
methyl phenyl]-urea) was selected as the prototype compound having a high affinity for
CCKB receptors on guinea pig cortical membranes (IC50 = 0.06 nM) and low affinity for
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rat pancreatic CCKA receptors (IC50 =130 nM), thus having a 2160-fold selectivity for
CCKB receptors [60]. This compound has similar CNS penetration to L-365, 260 [60].
The ureido-acetamide analogues RP 69758, RP 72540, and RP 73870 are reported
to be potent and selective CCKB receptor antagonists (Table 2, Figure 1) [61-63]. Each
ofthese analogues has greater than 1000-fold selectivity for CCKB receptors over CCKA
receptors with RP 73870 having greater than 3000-fold selectivity (Table 2). Each of
these compounds inhibits pentagastrin-stimulated acid secretion [61, 62], with RP 73870
causing half-maximal inhibition at 0.05 mg/Kg, i.v.) and was two-fold less potent than
famotidine, nine-fold more potent than CI-988, 26-fold more potent than cimetidine and
40-fold more potent than L- 365, 260 [62]. RP 73870, at a concentration sufficient to
block pentagastrin-stimulated secretion (0.3 mg/Kg, i.v.) has no effect on histamine-stim-
ulated acid secretion, whereas famotidine is equally potent for both [62]. RP 73870 pre-
vents aspirin-induced gastric mucosal injury and is about one-half as potent as cimetidine
and 3.5-times as potent as L-365, 260 [62]. RP 73870 also prevents cysteamine-induced
duodenal ulceration when given orally and is as potent as omeprazole or famotidine and
six-fold more potent than L- 365, 260 [62].
Two other classes of selective CCKB receptor antagonists are described (Table 2).
Various glutaramic acid derivatives are recently described that have a higher affinity for
the CCKB than the CCKA receptor such as CR 2194 (Table 2) [64]. From binding stud-
ies, CR 2194 only has a 23-fold selectivity [64], for CCKB receptors, however, it inhibits
pentagastrin-stimulated acid secretion in the dog, rat and cat [64]. A number of pyrazo-
lidinone analogues are CCKB selective antagonists [65, 66]. One of the most potent, LY
262, 691 (Table 2), inhibits CCK-8-induced depolarization in ventromedial hypothalamic
neurons and causes a specific decrease in the number of spontaneously active dopamine
cells in the central tegmental area, whereas CCKA receptor antagonists have no effect [65,
66]. This latter compound has a 370-fold selectivity for CCKB over CCKA receptors,
which is considerably less than the newer benzodiazepine analogues and the ureido-
acetamide analogues (Table 2).
III. CCK RECEPTOR-MEDIATED GASTRIC CHANGES IN WHICH AN;AGONISTS MIGHT BE THERAPEUTICALLY USEFUL
Before the possible therapeutic uses ofCCKB receptor antagonists in gastric secreto-
ry disorders is considered, it is important to understand what is known about the location
and function of CCKB gastrin receptors in the stomach. Limited data are available.
Because ofthe difficulty ofpurifying each cell type, the exact location ofCCKB receptors
in the stomach has only been determined in a few cell types. In the stomach, binding
and/or functional studies provide evidence forCCKA receptors on human [67], guinea pig
[18, 68] and rat chief cells [17, 69], whereas both CCKA and CCKB receptors are on
guinea pig chiefcells [18, 68, 70, 71] (Table 1). Both CCKA and CCKB receptors exist on
canine D cells and regulate somatostatin release [72]. CCKB receptors are found in canine
parietal cells [73], enterochromaffin cells (ECL cells) in dog and rat [74, 75], and report-
ed to be present in both neurons in the gastric circular muscle layer and in the myenteric
plexus in the stomach [76]. Pharmacological studies and binding studies provide evidence
for CCKB receptors on gastric smooth muscle [77, 78] (Table 1).
Evidence exists that activation of CCKB receptors in the stomach can stimulate acid
secretion [9, 79, 80]; release histamine from ECL cells in rat and dog [74, 75, 81]; stim-
ulate growth of the mucosa of the oxyntic gland area of the stomach increasing mucosal
weight, RNA, protein synthesis, and DNA synthesis [9, 79, 82]; stimulate ECL prolifera-
tion [83, 84], stimulate somatostatin secretion in in vitro preparations [72]; increase gas-
tric blood flow; increase pepsinogen secretion in some species and alter gastric motility
[9, 79, 80]. The responses that are thought physiological are the trophic effects [9, 79],
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effects on histamine release, acid secretion and perhaps effects on blood flow. For CCKB
receptor antagonists to be useful they need to inhibit one of these functions.
IV. POSSIBLE USE OF CCK RECEPTOR ANTAGONISTS
FOR INHIBITINd3ACID SECRETION
As reviewed above, it is well established that various classes of the newer CCKB
receptor antagonists, as well as L-365, 260, can inhibit acid secretion in animals [47, 57,
59, 61, 62, 85]. The only specific CCKB receptor antagonist examined in humans on
acid secretion is L-365, 260 [86]. In this study [86], in eight healthy male volunteers,
oral L- 365, 260 caused a dose-dependent inhibition of pentagastrin-stimulated acid
secretion, with the 50 mg dose causing half-maximal inhibition. In this study [86], it
was estimated that 50 mg of L-365, 260 caused acid inhibition equal to that caused by
five mg offamotidine. It was concluded that the acid inhibitory effect ofL-365, 260 was
modest and ofrelatively short duration and, therefore, was unlikely to be clinically use-
ful for this purpose [86]. Furthermore, in many animal studies the CCKB receptor antag-
onists are much more potent at inhibiting pentagastrin-stimulated acid secretion rather
than that caused by histamine or cholinergic agents, demonstrating the specificity of its
action for the CCKB receptor [47, 62]. This is in contrast to histamine H2-receptor
antagonists or H+-K+ ATPase inhibitors, which inhibit acid secretion stimulated by all
secretagogues. Each ofthese latter compounds inhibit acid secretion by all stimulus: the
H+-K+ATPase inhibitors because ofinhibiting a common late step in acid secretion, and
histamine H2-receptor antagonists by inhibiting the action of histamine which plays a
critical pivotal role in acid secretion mediated by all stimuli [81]. These results suggest
that even if a potent, long-acting CCKB antagonist is developed that causes prolonged
inhibition of pentagastrin-stimulated acid secretion, because of the specificity of its
action for gastrin-stimulated secretion, it is likely to be less useful than the H+-K+
ATPase inhibitors or histamine H2-blockers.
It could be argued that CCKB receptor antagonists might be particularly useful for
hypergastrinemic states associated with acid hypersecretion such as Zollinger-Ellison syn-
drome or antral G cell hyperfunction/hyperplasia [87, 88]. However, the H+-K+ ATPase
inhibitors are highly effective in these cases, controlling acid hypersecretion with once or
twice a day dosing [88, 89] and for the few patients who can not take these agents, hista-
mine H2-receptor antagonists are effective [88, 89]. It is unlikely CCKB receptor antago-
nists could improve on the acid-inhibitory effects offered by these agents even in hyper-
gastrinemic states, however it may have a use because of the trophic effects of gastrin in
these conditions as discussed below.
V. POSSIBLE USE OF CCK RECEPTOR ANTAGONISTS FOR INHIBITING
THE TROPHIC EFFECTS OF HYPERGASTRINEMIA
Recently, there has been increased concern about the consequences of prolonged
hypergastrinemia [87, 90-92]. This has occurred because moderate to severe gastroe-
sophageal reflux disease (GERD) is not uncommon and the H+-K+ATPase inhibitors are
the most effective agents for treatment ofGERD ofthis severity [93]. The chronic use of
H+-K+ATPase inhibitors for GERD and occasionally for peptic disease causes hypergas-
trinemia in 80 to 100 percent ofpatients [94, 95] with 30 percent ofpatients in one study
[94] having serum gastrin concentrations more than five-times the upper limit of normal.
It is well established that chronic hypergastrinemia causes an increased rate ofthe devel-
opment ofgastric carcinoid tumors in animals and man, some ofwhich are malignant [83,
84, 90, 96, 97]. Furthermore, it is controversial whether chronic hypergastrinemia
increases the risk of development or growth of colonic neoplasms [90, 98-101].
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Therefore, the possible use of a CCKB receptor antagonist in.chronic gastroesophageal
reflux disease might both control gastric acid hypersecretion and also inhibit the possible
trophic effects of the chronic hypergastrinemia. While theoretically attractive, with the
currently available information, it seems unlikely that CCKB receptor antagonists will be
useful for this purpose for a number of reasons. First, profound, prolonged inhibition of
gastric acid hypersecretion is needed to control symptoms and heal the mucosal lesions
in many patients with moderate to severe GERD. The H+-K+ ATPase inhibitors have
proven effective at accomplishing this and also have proven safe except for the risk of
hypergastrinemia. Patients with acid hypersecretory disorders have been treated with
omeprazole for 10 years and patients with idiopathic GERD up to seven years without
drug induced side-effects [94, 95, 102]. The CCKB receptor inhibitors developed so far
do not cause profound, prolonged inhibition of acid secretion, with L-365, 260 having
only a modest inhibition (50 mg orally equal to five mg famotidine), and the effect was
short-lived [86]. Secondly, CCKB antagonists are much more effective against gastrin-
stimulated secretion and have minimal effects on histamine or cholinergic-stimulated
secretion [47, 62]. This would suggest that their ability of CCKB receptor antagonists to
inhibit all forms ofacid secretion may be limited and, therefore, they would not cause the
profound, prolonged inhibition required to control GERD symptoms in patients with
moderate to severe disease. Lastly, in patients with idiopathic GERD or severe acid-pep-
tic disease, treatment for up to seven years with daily omeprazole resulted in a doubling
of the mean argyrophil cell count, a decrease in the percentage of patients with a normal
endocrine growth pattern, an increase in the percentage of patients with micronodular
hyperplasia, but no dysplastic lesions and no carcinoid tumors [95]. It was concluded [95]
that omeprazole is very likely safe for up to five years of continuous treatment in terms
of gastric changes. Even patients with Zollinger-Ellison syndrome with profound chron-
ic hypergastrinemia for 10 years have a very low rate of developing gastric carcinoid
tumors (0 percent in one study [103] and 0.6 percent in another study [87]). These data
suggest the risk of developing significant gastric mucosal changes due to even profound
hypergastrinemia is low with existing drugs for at least a five to 10-year period. Because
the existing acid antisecretory drugs are so effective, safe, and even with long-term treat-
ment the risk of chronic hypergastrinemia in terms of gastric mucosal changes is low, at
present there is little evidence to suggest that the routine use of a CCKB receptor antag-
onist would bejustified.
VI. POSSIBLE NONSECRETORY CLINICAL USES
OF CCKB RECEPTOR ANTAGONISTS
One of the main potential clinical uses of these agents might be in as a drug to pre-
vent panic attacks. These attacks are manifested as episodes of intense anxiety or fear
associated with cognitive and somatic symptoms. Repeated occurrence of panic attacks
occurs in two percent of the general population [104]. Familial and twin studies suggest
in some cases the disorder is inherited [104]. CCKB receptor agonists can precipitate these
attacks and CCKB receptor antagonists can prevent the attacks [104-106]. However, in a
recent placebo-controlled trial [40, 43], 88 patients with panic attacks were treated for six
weeks, with placebo or the CCKB receptor antagonist, L-365, 260 (30 mg, four times a
day), and the results demonstrated no difference in the occurrence ofthe panic attacks for
the two groups.
Numerous studies show gastrin can effect GI motility and CCKB receptors are known
to be present on smooth muscle cells of the GI tract [77, 79]. Also, gastrin-related pep-
tides have growth effects on a number of different tumors [98, 100, 101]. However, the
exact pathogenesis ofgastrin in either motility disorders or as an anticancer agent has not
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been defined, and it remains unclear whether CCKB receptor antagonists could be useful
clinically in these disorders.
VII. CONCLUSIONS
The recent development of five different classes of CCKB receptor antagonists that
have a high selectivity and high affinity for CCKB receptor antagonists will provide
important tools that will allow the role ofthese receptors to be defined in normal physiol-
ogy and in disease states. Because most non-peptide receptorantagonists ofvarious recep-
tors tend not to have species-related agonist activity seen with some peptide antagonists
[38, 40], these new non-peptide CCKB receptor antagonists should be generally useful
because they will likely function as antagonists without agonist activity in man and other
species. In which disease states CCKB receptor antagonists may be useful therapeutically
is at present unclear. Because a number of classes of potent, orally active, selective
inhibitors of acid secretion are currently widely used (histamine H2 receptor antagonists,
H+-K+ ATPase inhibitors), and because of the modest effects of CCKB receptor antago-
nists in inhibition of acid secretion, the CCKB receptor antagonists will unlikely be ther-
apeutically useful in this role. It is more likely they will therapeutically useful for certain
CNS actions ofCCK such as its ability to induce panic attacks or possibly as an antipro-
liferative agent.
REFERENCES
1. Mutt, V. and Jorpes, J.E. Structure of porcine cholecystokinin-pancreozymin. 1. Cleavage with
thrombin and with trypsin. Eur. J. Biochem. 6:156-162, 1968.
2. Jorpes, J.E. and Mutt, V. Handbook ofExperimental Pharmacology. Secretin, cholecystokinin,
pancreozymin. Berlin, Heidelberg: Springer-Verlag; 1973.
3. Huang, S.C., Yu, D.H., Wank, S.A., Mantey, S., Gardner, J.D., and Jensen, R.T. Importance of
sulfation of gastrin or cholecystokinin (CCK) on affinity for gast CCK receptors. Peptides 10
(4):785-789, 1989.
4. Liddle, R.A. Cholecystokinin. In: Walsh, J.H. and Dockray, G.J., eds. Gut Peptides. New York:
Raven Press; 1994, pp. 175-216.
5. Jensen, R.T. Cholecystokinin. In: Jensen, R.T. ed. Regulatory Peptide Letter. Ann Arbor, MI:
MED Pub, Inc.; 1994, pp. 1-16.
6. Rehfeld, J.F. and van Solinge, W.W. The tumor biology of gastrin and cholecystokinin. Adv.
Cancer Res. 63:295-347, 1994.
7. de Castiglione, R. Structure-activity relationships in ceruletide-like peptides. In: Bonfils, S.,
Fromageot, P., and Rosselin, G., eds. First international symposium on hormonal receptors in
digestive tract physiology, INSERM Symposium No. 3. New York: Elsevier/North Holland
Biomedical Press; 1977, pp. 33-42.
8. Jensen, R.T. Cholecystokinin (CCK): Advances in its biochemistry, cell biology and physiolo-
gy. In: Jensen, R.T. ed. Cholecystokinin. Ann Arbor, MI: MED Pub., Inc.; 1994, pp. 1-5.
9. Walsh, J.H. Gastrin. In: Walsh, J.H., and Dockray, G.J., eds. Gut Peptides. New York: Raven
Press; 1994, pp.. 75-121.
10. Moran, T.H. Cholecystokinin in the central nervous system. Regul. Pept. Lett. 6:10-15, 1994.
11. Johnson, L.R. and McCormack, S.A. Regulation of gastrointestinal mucosal growth. In:
Johnson, L.R., Alpers, D.H., Christensen, J., Jacobson, E.D., and Walsh, J.H., eds. Physiology
ofthe Gastrointestinal Tract. NewYork: Raven Press; 1994, pp. 611-641.
12. Jensen, R.T. Receptors on pancreatic acinar cells. In: Johnson, L.R., Jacobsen, E.D.,
Christensen, J., Alpers, D.H., and Walsh, J.H., eds. Physiology of the Gastrointestinal Tract,
Third edition. NewYork: Raven Press; 1994, pp. 1377-1446.
13. Karlsson, S. and Ahren, B. CCK-8-stimulated insulin secretion in vivo is mediated by CCKA
receptors. Eur. J. Pharmacol. 213:145-146, 1992.
14. Fried, M., Erlacher, U., Schwizer, W., Lochner, C., Koerfer, J., Beglinger, C., Jansen, J.B.,
Lamers, C.B., Harder, F., Bischof-Delaloye, A., Stalder, G.A., and Rovati, L. Role ofcholecys-
tokinin in the regulation ofgastric emptying and pancreatic enzyme secretion in humans: stud-
ies with thecholecystokinin-receptor antagonist loxiglumide. Gastroenterology 101(2):503-511,
1991.Jensen: CCKB-R antagonists 255
15. Meyer, B.M., Werth, B.A., Beglinger, C., Hildebrand, P., Jansen, J.B., Zach, D., Rovati, L.C.,
and Stalder, G.A. Role of cholecystokinin in regulation of gastrointestinal motor functions.
Lancet 2:12-15, 1989.
16. Lloyd, D.C., Raybould, H.E., and Walsh, J.H. Cholecystokinin inhibits gastric acid secretion
through type "A" cholecystokinin receptors and somatostatin in rats. Am. J. Physiol. 263(3 Pt
1):G287-G292, 1992.
17. Tazi-Saad, K., Chariot, J., and Roze, C. Control ofpepsin secretion by regulatory peptides in the
rat stomach: comparison with acid secretion. Peptides 13:233-239, 1992.
18. Qian, J.M., Rowley, W.H., andJensen, R.T. Gastrin andCCK activate phospholipase C and stim-
ulate pepsinogen release by interacting with two distinct receptors. Am. J. Physiol. 264:G718-
G727, 1993.
19. Beglinger, C., Hildebrand, P., Meier, R., Bauerfeind, P., Hasslocher, H., Urscheler, N., Delco, F.,
Eberle, A., and Gyr, K. A physiological role for cholecystokinin as a regulator ofgastrin secre-
tion. Gastroenterology 103:490-495, 1992.
20. Bradwejn, J. Neurobiological investigations into the role ofcholecystokinin in panic disorder. J.
Psychiatr. Neurosci. 18:178-188, 1993.
21. Wank, S.A., Pisegna, J.R., and DeWeerth, A. Cholecystokinin receptor family. Molecular
cloning, structure, and functional expression in rat, guinea pig, and human. Ann. N.Y. Acad. Sci.
713:49-66, 1994.
22. Jensen, R.T., Wank, S.A., Rowley, W.H., Sato, S., and Gardner, J.D. Interaction of CCK with
pancreatic acinar cells. Trends Pharmacol Sci 10:418-423, 1989.
23. Wank, S.A. Cholecystokinin receptors. Am. J. Physiol. 269:G628-G646, 1995.
24. Kopin, A.S., Lee,Y.M., McBride, E.W., Miller, L.J., Lu, M., Lin, H.Y., Kolakowski, L.F., Jr., and
Beinborn, M. Expression cloning and characterization of the canine parietal cell gastrin recep-
tor. Proc. Natl. Acad. Sci. USA 89:3605-3609, 1992.
25. Jensen, R.T., Qian, J.M., Lin, J.T., Mantey, S.A., Pisegna, J.R., and Wank, S.A. Distinguishing
multiple CCK receptor subtypes: studies with guinea pig chiefcells and transfected human CCK
receptors. Ann. N. Y. Acad. Sci. 713:88-106, 1994.
26. Kopin, A.S., Beinborn, M., Lee, Y.M., McBride, E.W., and Quinn, S.M. The CCK-B/gastrin
receptor: identification ofamino acids that determine non-peptide antagonist affinity. Ann. N.Y.
Acad. Sci. 713:67-78, 1995.
27. Lee, YM., Beinborn, M., McBride, E.W., Lu, M., Kolakowski, L.F., Jr., and Kopin, A.S. The
human brain cholecystokinin-B/gastrin receptor. J. Biol. Chem. 268:8164-8169, 1993.
28. Lin, C.W., Holladay, M.W., Witte, D.G., Miller, T.R., Wolfram, C.A., Bianchi, B.R., Bennett,
M.J., and Nadzan, A.M. A71378: a CCK agonist with high potency and selectivity for CCK-A
receptors. Am. J. Physiol. 258:G648-G651, 1990.
29. Charpentier, B., Pelaprat, D., Durieux, C., Dor, A., Reibaud, M., Blanchard, J.C., and Roques,
B.P. Cyclic cholecystokinin analogues with high sensitivity for central receptors. Proc. Natl.
Acad. Sci. USA 85:1968-1972, 1988.
30. Knapp., R.J., Vaughn, L.K., Fang, S.N., Bogert, C.L., Yamamura, M.S., Hruby, V.J., and
Yamamura, H.I. A new, highly selective CCK-B receptor radioligand ([3H][N-methyl-Nle28,
31]CCK26-33): evidence for CCK-B receptor heterogeneity. J. Pharmacol. Exp. Ther.
255:1278-1286, 1990.
31. Yu, D.H., Huang, S.C., Wank, S.A., Mantey, S., Gardner, J.D., and Jensen, R.T. Pancreatic
receptors for cholecystokinin: Evidence for three receptor classes. Am. J. Physiol. 258:G86-
G95, 1990.
32. Jensen, R.T. and Gardner, J.D. Cholecystokinin receptor antagonists in vivo. In: Adler, G., and
Beglinger, C., eds. Cholecystokinin Antagonists in Gastroenterology: Basic and Clinical
Studies. Heidelberg, West Germany: Springer-Verlag GmbH and Co.; 1991, pp. 93-111.
33. Beinborn, M., Lee, Y.M., McBride, E.W., Quinn, S.M., and Kopin, A.S. A single amino acid of
the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists.
Nature 362:348-350, 1993.
34. Schmassmann, A., Garner, A., Flogerzi, B., Hasan, M.Y., Sanner, M., Varga, L., and Halter, F.
Cholecystokinin type B receptor antagonist PD-136, 450 is a partial secretory agonist in the
stomach and a full agonist in the pancreas ofth rat. Gut 35:270-274, 1994.
35. Koop, I., Eissele, R., Richter, S., Patberg, H., Meyer, F., Mossner, J., Arnold, R., and Koop, H.
A new CCK-B/gastrin receptor antagonist acts as an agonist on the rat pancreas. Int. J.
Pancreatol. 15:215-222, 1994.
36. Hughes, J., Boden, P., Costall, B., Domeney, A., Kelly, E., Horwell, D.C., Hunter, J.C., Pinnock,
R.D., and Woodruff, G.N. Development of a class of selective cholecystokinin type B receptor
antagonists having potent anxiolytic activity. Proc. Natl. Acad. Sci. USA 87:6728-6732, 1990.256 Jensen: CCKB-R antagonists
37. Hocker, M., Hughes, J., Folsch, U.R., and Schmidt, W.E. PD 135158, aCCKB/gastrin receptor
antagonist, stimulates rat pancreatic enzyme secretion as a CCKA receptor agonist. Eur. J.
Pharmacol. 242:105-108, 1993.
38. Wang, L.H., Coy, D.H., Taylor, J.E., Jiang, N.Y., Moreau, J.P., Huang, S.C., Frucht, H., Haffar,
B.M., and Jensen, R.T. Des-Met carboxyl-terminally modified analogues ofbombesin function
as potent bombesin receptor antagonists, partial agonists, or agonists. J. Biol. Chem.
265(26):15695-15703, 1990.
39. Coy, D., Wang, L.H., Jiang, N.Y., and Jensen, R. Short chain bombesin pseudopeptides with
potent bombesin receptor antagonistic activity in rat and guinea pig pancreatic acinar cells.
Europ. J. Pharmacol. 190:31-38, 1990.
40. Jensen, R.T. and Coy, D.H. Progress in the development of potent bombesin receptor antago-
nists. Trends Pharmacol Sci 12 (# 1/2):13-19, 1991.
41. Gu, Z.F., Rossowski, W.J., Coy, D.H., Pradhan, T., andJensen, R.T. Chimeric analogs that func-
tion as antagonists in the CNS are full agonists in gastrointestinal smooth muscle. J. Pharmacol.
Exp. Ther. 266:912-918, 1993.
42. Howard, J.M., Knight, M., Jensen, R.T., and Gardner, J.D. Discovery of an analogue of chole-
cystokinin with partial agonist activity. Am. J. Physiol. 247:G261-G264, 1984.
43. Huang, S.C., Zhang, L., Chiang, H.C., Wank, S.A., Maton, P.N., Gardner, J.D., and Jensen, R.T.
Benzodiazepine analogues L-365, 260 and L-364, 718 as gastrin and pancreatic CCK receptor
antagonists. Am. J. Physiol. 257:G169-G174, 1989.
44. Pisegna, J.R., DeWeerth, A., and Wank, S.A. Molecular cloning ofthe human brain and gastric
cholecystokinin receptor: structure, functional expression and chromosomal localization.
Biochem. Biophys. Res. Commun. 189:296-303, 1992.
45. Kopin, A.S., McBride, E.W., Quinn, S.M., Kolakowski, L.F., and Beinbom, M. The role of the
cholecystokinin-B/gastrin receptor transmembrane domains in determining affinity for subtype-
selective ligands. J. Biol. Chem. 270:5019-5023, 1995.
46. Freidinger, R.M. Synthesis of non-peptide CCK antagonists. In: Dourish, C.T., Cooper, S.J.,
Iversen, S.D., and Iversen, L.L., eds. Multiple cholecystokinin receptors in the CNS. NewYork:
Oxford University Press; 1992, pp. 8-27.
47. Nishida, A., Miyata, K., Tsutsumi, R., Yuki, H., Akuzawa, S., Kobayashi, A., Kamato, T., Ito,
H., Yamano, M., Katuyama, Y., Satoh, M., Ohta, M., and Honda, K. Pharmacologial profile of
(R)-1-[2, 3-dihydro-1-(2'-methyl-phenacyl)-2-oxo-5-phenyl-1 H-1, 4-benzodiazepin-3-yl]- 3-
(3-ethylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor
antagonist, in vitro and in vivo. J. Pharmacol. Exp. Ther. 269:725-731, 1994.
48. Ohtsuka, T., Kotaki, H., Nakayama, N., Itezono, Y., Shimma, N., Kudoh, T., Kuwahara, T.,
Arisawa, M., Yokose, K., and Seto, H. Tetronothiodin, a novel cholecystokinin type-B receptor
antagonist produced by Streptomyces sp. NR0489. II. Isolation, characterization and biological
activities. J. Antibiot. (Tokyo) 46:11-17, 1993.
49. Ohtsuka, T., Nakayama, N., Itezono, Y., Shimma, N., Kuwahara, T., Yokose, K., and Seto, H.
Tetronothiodin, a novel cholecystokinin type-B receptor antagonist produced by Streptomyces
sp. NR0489. III. Structural elucidation. J. Antiobiot. (Tokyo) 46:18-24, 1993.
50. Kuwahara, T., Kudoh, T., Nakano, A., Yoshizaki, H., Takamiya, M., Nagase, H., and Arisawa,
M. Species specificity of pharmacological characteristics of CCK-B receptors. Neurosci. Lett.
158:1-4, 1993.
51. Lam, Y.K., Bogen, D., Chang, R.S., Faust, K.A., Hensens, O.D., Zink, D.L., Schwartz, C.D.,
Zitano, L., Garrity, G.M., and Gagliardi, M.M. Novel and potent gastrin and brain cholecys-
tokinin antagonists from Streptomyces olivaceus. Taxonomy, fermentation, isolation, chemical
conversions, and physico-chemical and biochemial properties. J. Antibiot. (Tokyo) 44:613-625,
1991.
52. Chang, R.S., Lotti, V.J., Monaghan, R.L., Bimbaum, J., Stapley, E.O., Goetz, M.A., Albers-
Schonberg, G., Patchett,A.A., Liesch, J.M., Hensens, O.D., and Springer, J.P. A potent non-pep-
tide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus
Allicaceus. Science 230:177-179, 1985.
53. Kuwahara, T., Kudoh, T., Nagase, H.,Takamiya, M., Nakano,A., Ohtsuka,T.,Yoshizaki, H., and
Arisawa, M. Tetronothiodin, a novel CCK receptor ligand, antagonizes cholecystokinin-
induced Ca2+ mobilization in a pituitary cellfine. Eur. J. Pharmacol. 221:99-105, 1992.
54. Freedman, S.B., Patel, S., Smith, A.J., Chapman, K., Fletcher, A., Kemp, J.A., Marshall, G.R.,
Hargreaves, R.J., Scholey, K., Mellin, E.C., DiPardo, R.M., Bock, M.G., and Freidinger, R.M.
A secondgeneration ofnon-peptide cholecystokinin receptor antagonists and theirpossible ther-
apeutic potential. Ann. N. Y. Acad. Sci. 713:312-318, 1994.Jensen: CCKB-R antagonists 257
55. Bock, M.G., DiPardo, R.M., Mellin, E.C., Newton, R.C., Veber, D.F., Freedman, S.B., Smith,
A.J., Patel, S., Kemp, J.A., and Marshall, G.R. Second-generation benzodiazepine CCK-B
antagonists. Development ofsubnanomolar analogs with selectivity and watersolubility. J. Med.
Chem. 37:722-724, 1994.
56. Showell, G.A., Bourrain, S., Neduvelil, J.G., Fletcher, S.R., Baker, R., Watt,A.P., Fletcher,A.E.,
Freedman, S.B., Kemp, J.A., and Marshall, G.R. High-affinity and potent, water-soluble 5-
amino-i, 4-benzodiazepine CCKB/gastrin receptor antagonists containing a cationic solubiliz-
ing group. J. Med. Chem. 37:719-721, 1994.
57. Patel, S., Smith, A.J., Chapman, K.L., Fletcher, A.E., Kemp, J.A., Marshall, G.R., Hargreaves,
R.J., Ryecraft, W., Iversen, L.L., Iversen, S.D., Baker, R., Showell, G.A., Bourrain, S.,
Neduvelil, J.G., Matassa, V.G., and Freedman, S.B. Biological properties ofthe benzodiazepine
amidine derivative L-740, 093, acholecystokinin-B/gastrin receptor antagonist with high affini-
ty in vitro and high potency in vivo. Mol. Pharmacol. 46:943-948, 1994.
58. Patel, S., Chapman, K.L., Smith, A.J., Heald, A., and Freedman, S.B. Use of ex vivo binding to
estimate brain penetration and central activity of CCK-B antagonists. Ann. N. Y. Acad. Sci.
713:360-363, 1993.
59. Nishida, A., Takinami, Y., Yuki, H., Kobayashi, A., Akuzawa, S., Kamato, T., Ito, H., Yamano,
M., Nagakura,Y., and Miyata, K. YM022 t(R)-1-[2, 3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-
phenyl-1H-1, 4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea), a potent and selective
gastrin/choleystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats. J.
Pharmacol Exp. Ther. 270:1256-1261, 1994.
60. Bock, M.G., DiPardo, R.M., Newton, R.C., Bergman, J.M., Veber, D.F., Freedman, S.B., Smith,
A.J., Chapman, K.L., Patel, S., Kemp, J.A., Marshall, G.R., and Freidinger, R.M. Selective non-
peptide ligands for an accommodating peptide receptor. Imidazobenzodiazepines as potent
cholecystokinin type B receptor antagonists. Bioorganic Medicinal Chem. 2:987-998, 1994.
61. Bertrand, P., Bohme, G.A., Durieux, C., Guyon, C., Capet, M., Jeantaud, B., Boudeau, P.,
Ducos, B., Pendley, C.E., Martin, G.E., Floch, A., and Doble, A. Pharmacological properties of
ureido-acetamides, new potent and selective non-peptide CCK-B/gastrin receptor antagonists.
Europ. J. Pharmacol. 262:233-245, 1994.
62. Pendley, C.E., Fitzpatrick, L.R., Capolino, A.J., Davis, M.A., Esterline, N.J., Jakubowska, A.,
Bertrand, P., Guyon, C., Dubroeucz, M.C., and Martin, G.E. RP 73870, a gastrin/cholecystokin-
B receptor antagonist with potent anti-ulcer activity in the rat. J. Pharmacol. Exp. Ther.
273:1015-1022, 1995.
63. Bohme, G.A., Bertrand, P., Guyon, C., Capet, M., Pendley, C., Stutzmann, J.M., Doble, A.,
Dubroeucz, M.C., Martin, G., and Blanchard, J.C. The ureidoacetamides, a novel family ofnon-
peptide CCK-B/gastrin antagonists. Ann. N. Y. Acad. Sci. 713:118-120, 1994.
64. Makovec, F., Peris, W., Revel, L., Giovanetti, R., Mennuni, L., and Rovati, L.C. Structure-anti-
gastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives. J. Med.
Chem. 35:28-38, 1992.
65. Howbert, J.J., Lobb, K.L., Brown, R.F., Reel, J.K., Neel, D.A., Mason, N.R., Mendelsohn, L.G.,
Hodgkiss, J.P., and Kelly, J.S. A novel series ofnon-peptide CCK and gastrin antagonists: med-
icinal chemistry and electrophysiological demonstration of antagonism. In: Dourish, C.T.,
Cooper, S.J., Iversen, S.D., and Iversen, L.L., eds. New York: Oxford University Press; 1992,
pp. 28-37.
66. Rasmussen, K., Czachura, J.F., Stockton, M.E., and Howbert, J.J. Electrophysiological effects
of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain
dopamine neurons. J. Pharmacol. Exp. Ther. 264:480-488, 1993.
67. Lanas, A.I., Anderson, J.W., Uemura, N., and Hirschowitz, B.I. Effects of cholingergic, hista-
minergic, and peptidergic stimulation on pepsinogen secretion by isolated human peptic cells.
Scand. J. Gastroenterol. 29:678-683, 1994.
68. Pradhan, T.K., Qian, J.M., Sutliff, V.E., III, Mantey, S.A., and Jensen, R.T. Identification of
CCK-A receptors on chiefcells with the use of a novel, highly selective ligand. Am. J. Physiol.
268:G605-G612, 1995.
69. Tang, L.H., Miller, M.D., Goldenring, J.R., Modlin, I.M., and Hersey, S.J. Partial agonism by
gastrin for a cholecystokinin receptor mediating pepsinogen secretion. Am. J. Physiol.
265:G865-G872, 1993.
70. Sutliff, V.E., Chemer, J.A., Jensen, R.T., and Gardner, J.D. Binding of 1251-CCK-8 and 1251-
gastrin-I to dispersed chiefcells from guinea-pig stomach. Biochim. Biophys. Acta. 1052:9-16,
1990.258 Jensen: CCKB-R antagonists
71. Lin, C.W., Bianchi, B.R., Miller, T.R., Witte, D.G., and Wolfram, C.A. Both CCK-A and CCK-
B/gastrin receptors mediate pepsinogen release in guinea pig gastric glands. Am. J. Physiol.
262:G1113-G1120, 1992.
72. DelValle, J., Chiba, T., Park, J., andYamada, T. Distinct receptors for cholecystokinin and gas-
trin on canine fundic D-cells. Am. J. Physiol. 264:G81 I-G815, 1993.
73. Soll,A.H., Amirian, D.A., Thomas, L.P., Reedy, T.J., andElashoff, J.D. Gastrin receptors on iso-
lated canine parietal cells. J. Clin. Invest. 73:1434-1447, 1984.
74. Chuang, C.N., Tanner, M., Chen, M.C., Davidson, S., and Soll, A.H. Gastrin induction ofhista-
mine release from primary cultures ofcanine oxyntic mucosal cells. Am. J. Physiol. 263:G460-
G465, 1992.
75. Prinz, C., Scott, D.R., Hurwitz, D., Helander, H.F., and Sachs, G. Gastrin effects on isolated rat
enterochromaffin-like cells in primary culture. Am. J. Physiol. 267:G663-G675, 1994.
76. Mantyh, C.R., Papp.as, T.N., and Vigna, S.R. Localization of cholecystokinin and cholecys-
tokininB/gastrin receptors in the canine uppergastrointestinal tract.Gastroenterology 107:1019-
1030, 1994.
77. Grider, J.R. and Makhlouf, G.M. Distinct receptors for cholecystokinin and gastrin on muscle
cells of stomach and gallbladder. Ann. N. Y. Acad. Sci. 259:G184-G190, 1990.
78. Menozzi, D., Gardner, J.D., Jensen, R.T., and Maton, P.N. Properties ofreceptors forgastrin and
CCK on gastric smooth muscle cells. Am. J. Physiol. 257:G73-G79, 1989.
79. Dockray, G.J. and Gregory, R.A. Gastrin. In: Schultz, S.G., Makhlouf, G.M. and Rauner, B.B.,
eds. Handbook ofPhysiology: The Gastrointestinal System. NewYork: Oxford University Press;
1989, pp. 311-336.
80. Lloyd, K.C. and Walsh, J.H. Gastric secretion. In: Walsh, J.H., and Dockray, G.J., eds. Gut
Peptides. New York: Raven Press; 1994, pp. 633-654.
81. Waldum, H.L., Sandvik, A.K., and Brenna, E. Gastrin: Histamine-releasing activity. In: Walsh,
J.H., ed. Gastrin. New York: Raven Press, Ltd. 1993, pp. 259-271.
82. Willems, G. Trophic action of gastrin on specific target cells in the gut. In: Mignon, M., and
Jensen, R.T., eds. Endocrine Tumors of the Pancreas: Recent Advances in Research and
Management. Basel, Switzerland: S. Karger; 1995, pp. 30-44.
83. Hakanson, R. and Sundler, F.H. Regulation of gastric endocrine cell proliferation. In: Walsh,
J.H. ed. Gastrin. New York: Raven Press, Ltd. 1993, pp. 307-318.
84. Hakanson, R. and Sundler, F. Mechanisms for the development ofgastric carcinoids. Digestion
35(suppl):1-151, 1986.
85. Eissele, R., Koop, H., Bothe-Sandfort, E., and Arnold, R. Effect ofgastrin receptor antagonists
on gastric acid secretion and gastrin and somatostatin release in the rat stomach. Digestion
53:179-188, 1992.
86. Murphy, M.G., Sytnik, B., Kovacks, T.O.G., Mertz, H., Ewanik, D., Shingo, S., Lin, J.H., Gertz,
B.J., and Walsh, J.H. The gastrin-receptor antagonist L-365, 260 inhibits stimulated acid secre-
tion in humans. Clin. Pharmacol. Ther. 54:533-539, 1993.
87. Jensen, R.T. Gastrinoma as a model forprolonged hypergastrinemia in man. In: Walsh, J.H., ed.
Gastrin. NewYork, NY: Raven Press Publishing Co. 1993, pp. 373-393.
88. Jensen, R.T. and Gardner, J.D. Gastrinoma. In: Go, V.L.W., DiMagno, E.P., Gardner, J.D.,
Lebenthal, E., Reber, H.A., and Scheele, G.A., eds. The Pancreas: Biology, Pathobiology and
Disease. NewYork, NY: Raven Press Publishing Co.; 1993, pp. 931-978.
89. Metz, D.C. and Jensen, R.T. Advances in gastric antisecretory therapy in Zollinger-Ellison syn-
drome. In: Mignon, M., and Jensen, R.T., eds. Endocrine Tumors of the Pancreas: Recent
advances in research and management. Basel, Switzerland: S. Karger; 1995, pp. 240-257.
90. Creutzfeldt, W. The achlorhydria-carcinoid sequence: role ofgastrin. Digestion 39:61-79, 1988.
91. Maton, P.N. and Dayal, Y. Clinical implications of hypergastrinemia. In: Zakim, D., and
Dannenberg, A.J., eds. Peptic ulcer disease and other acid-related disorders. Armonk, NY:
Academic Research Associates; 1991, pp. 213-246.
92. Wormsley, K.G. Is chronic long-term inhibition of gastric secretion really dangerous. Scand. J.
Gastroenterol. 146(suppl):166-174, 1988.
93. Hetzel, D.J., Dent, J., Reed, W.D., Narielvala, F.M., MacKinnon, M., McCarthy, J.H., Mitchell,
B., Beveridge, B.R., Laurence, B.H., Gibson, G.G., Grant,A.K., Shearman, D.J., Whitehead, R.,
and Buckle, P.J. Healing and relapse of severe peptic esophagitis after treatment with omepra-
zole. Gastroenterology 95:903-912, 1988.
94. Jansen, J.B., Klinkenberg-Knol, E.C., Meuwissen, S.G., De Bruijne, J.W., Festen, H.P., Snel, P.,
Luckers,A.E., Biemond, I., and Lamers, C.B. Effect oflong-term treatment with omeprazole on
serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis.
Gastroenterology 99:621-628, 1990.Jensen: CCKB-R antagonists 259
95. Lamberts, R., Creutzfeldt, W., Struber, H.G., Brunner, G., and Solcia, E. Long-term omepra-
zole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis.
Gastroenterology 104:1356-1370, 1993.
96. Ekman, L., Hansson, E., Havu, N., Carlsson, E., and Lundberg, C. Toxicological studies on
omeprazole. Scand. J. Gastroenterol. 20(suppl):53-69, 1985.
97. Havu, N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibi-
tion of gastric secretion. Digestion 35(suppl):42-55, 1986.
98. Townsend, C.M., Jr., Ishizuka, J., and Thompson, J.C. Gastrin trophic effects on transplanted
colon cancer cells. In: Walsh, J.H. ed. Gastrin. New York: Raven Press; 1993, pp. 407-417.
99. Dickinson, C.J. Relationship ofgastrin processing to colon cancer (Editorial). Gastroenterology
109:1384-1388, 1995.
100.Rehfeld, J.F. Gastrin and colorectal cancer: A never-ending dispute? (Editorial). Gastroenterol.
108:1307-1310, 1995.
101.Orbuch, M., Venzon, D.J., Lubensky, I.A., Weber, H.C., Gibril, F., and Jensen, R.T. Prolonged
hypergastrinemia does not increase the frequency of colonic neoplasia in patients with
Zollinger-Ellison syndrome. Dig. Dis. Sci. 41:604-613, 1996.
102.Metz, D.C., Strader, D.B., Orbuch, M., Koviach, P.D., Feigenbaum, K.M., andJensen, R.T. Use
of omeprazole in Zollinger-Ellison: a prospective nine-year study of efficacy and safety.
Aliment. Pharmacol. Ther. 7:597-610, 1993.
103.Lehy, T., Cadiot, G., Mignon, M., Ruszniewski, P., and Bonfils, S. Influence of multiple
endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syn-
drome. Gut 33:1275-1279, 1992.
104.Harro, J., Vasar, E., and Bradwejn, J. CCK in animal and human research on anxiety. Trends
Pharmacol. Sci. 14:244-249, 1993.
105. van Megen, H.J., Westenberg, H.G., den Boer, J.A., Haigh, J.R., and Traub, M. Pentagastrin
induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmacol. (Berl)
114:449-455, 1994.
106.Bradwejn, J., Koszycki, D., Couetoux du Tertre, A., van Megen, H., den Boer, J., and
Westenberg, H. The panicogenic effects ofcholecystokinin-tetrapeptide are antagonized by L-
365, 260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch.
Gen. Psych. 51:486-493, 1994.